Targeting Cholinergic System to Modulate Liver Injury

Ravirajsinh N Jadeja1, Vikrant P Rachakonda2, Sandeep Khurana1,3

  • 1Digestive Health Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, United States.

Current Drug Targets
|June 20, 2017
PubMed

Insights

Parasympathetic nerves regulate liver injury and regeneration through acetylcholine release. Understanding these neural pathways offers potential therapeutic targets for liver disease.

Area of Science:

  • Hepatology
  • Neurogastroenterology
  • Cellular Biology

Background:

  • Parasympathetic innervation plays a crucial role in regulating liver injury and regeneration.
  • The vagus nerve is the primary source of parasympathetic input to the liver.
  • Current models often focus on vagal nerve activity, limiting insight into post-neuronal mechanisms.

Purpose of the Study:

  • To review the current understanding of cholinergic regulation in liver injury.
  • To explore the role of neurotransmitters and cellular receptors in liver pathophysiology.
  • To identify potential therapeutic targets for treating liver injury.

Main Methods:

  • Review of existing literature on vagus nerve stimulation and transection in animal models.
  • Analysis of studies utilizing gene-silencing and pharmacological approaches.
  • Consideration of advancements in organ- and cell-specific transgenic mice models.

Main Results:

  • Acetylcholine (ACh) released by the hepatic vagus nerve activates muscarinic and nicotinic receptors in liver cells.
  • Vasoactive intestinal peptide (VIP) also modulates liver injury and hemodynamics.
  • Gene-silencing and pharmacological studies have clarified the roles of specific receptors and liver cell populations.

Conclusions:

  • Cholinergic signaling significantly impacts liver injury and regeneration.
  • Further research using advanced genetic models will enhance understanding of neural regulation in liver disease.
  • Targeting cholinergic pathways presents promising therapeutic avenues for liver injury.

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.8K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.7K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
2.0K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.9K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.5K